Capecitabine and Mitomycin C for Colorectal Cancer
Author Information
Author(s): Chong G, Dickson J L B, Cunningham D, Norman A R, Rao S, Hill M E, Price T J, Oates J, Tebbutt N
Primary Institution: Royal Marsden Hospital
Hypothesis
The combination of capecitabine and mitomycin C may improve outcomes in patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan.
Conclusion
Capecitabine in combination with mitomycin C is an effective treatment for metastatic colorectal cancer that is resistant to previous therapies.
Supporting Evidence
- The objective response rate was 15.2%.
- 48.5% of patients had stable disease.
- Median overall survival was 9.3 months.
- Grade 3 toxicities included palmar-plantar erythema in 16.7% of patients.
- Symptomatic improvement occurred for pain, bowel symptoms, and dyspnoea.
Takeaway
This study tested a new medicine combination for patients with a tough type of cancer, and it helped some people feel better and live longer.
Methodology
A phase II open-label study was conducted with patients who had previously received two lines of chemotherapy for metastatic colorectal cancer.
Potential Biases
Potential biases may arise from the open-label design and the specific patient selection criteria.
Limitations
The study was limited by a small sample size and the lack of a control group.
Participant Demographics
Median age was 64 years, with 78% of patients having a performance status of 0-1.
Statistical Information
P-Value
0.024
Confidence Interval
95% CI: 6.9–11.7
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website